Improved hemostasis with the combination of a heparin-coated circuit and aprotinin prime during open-heart surgery: potentiating effect on platelet preservation
Aprotinin administration with or without a heparin-coated circuit is expected to modulate subclinical plasma coagulation and fibrinolysis and platelet function during cardiopulmonary bypass. We studied the effect of the application of both, either one, or neither of an aprotinin prime (100 million KIU) and heparin-coated circuit in 32 consecutive patients undergoing coronary artery bypass surgery randomly divided into four groups of 8 patients each. Aprotinin was not used with the non-heparin-coated circuit in the control group. Levels of fibrinopeptide A were significantly lower in the heparin-coated circuit groups (P<0.05–0.01), irrespective of an aprotinin prime. D-dimer levels in the control group were significantly higher than in the other groups (P<0.05–0.01). The preservation rates of platelet count and function (acceleration of coagulation by platelet activating factor) in the control group were significantly lower than in the other three groups (P<0.05–0.01). Platelet preservation in the aprotinin plus heparin-coated group was significantly better than in the aprotinin only and the heparin-coated only groups (P<0.05). The amount of mediastinal drainage and the units of blood transfusion were significantly reduced in the two aprotinin groups, irrespective of heparin-coated use (P<0.01). The values in the aprotinin plus heparin-coated group were significantly less than the values in the heparin-coated only group (P<0.05). The heparin-coated circuit was beneficial for suppressing subclinical plasma coagulation and fibrinolysis and for preserving platelets. Addition of the minimal-dose aprotinin prime further preserved about a further reduction in postoperative blood loss and blood requirements.
Key wordsHearin-coated Cardiopulmonary bypass Aprotinin
Unable to display preview. Download preview PDF.
- 7.Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation 1992;86(suppl II):II-405–II-409Google Scholar
- 16.Jansen PGM, te Velthuis H, Huybregts RAJM, Paulus R, Bulder ER, van der Spoel HI, Bezemer PD, Slaats Ed H, Eijsman L, Wildevuur CRH. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995;110:829–834PubMedCrossRefGoogle Scholar
- 20.Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076–1082PubMedGoogle Scholar
- 22.Kirklin JK, Kirklin JW. Cardiopulmonary bypass for cardiac surgery. In: Sabiston DC Jr, Spencer FC (eds) Surgery of the chest, Philadelphia: Saunders, 1990;1107–1125Google Scholar
- 23.Gu YJ, van Oeveren W, van der Kamp KWHJ, Akkerman C, Boonstra PW, Wilderevuur CRH. Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991;6:220–225Google Scholar
- 25.Gorman RC, Ziats NP, Rao AK, Gikakis N, Sun L, Khan MMH, Stenach N, Sapatnekar S, Chouhan V, Gorman JH, Niewiarowski S, Colman RW, Anderson JM, Edmunds LH. Surface-bonded heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:1–12.PubMedCrossRefGoogle Scholar
- 26.Shiiya N, Ikeda H, Matsuzaki K, Watanabe M, Matsui Y, Sekiguchi S, Yasuda K. Does a heparin-coated cardiopulmonary bypass circuit favorably affect hemostatic function? (in Japanese with English abstract). Jpn J Artif Organs 1998;27:418–422Google Scholar
- 31.Boosstra PW, Gu YJ, Akkerman C, Haan J, Huyzen R, von Oeveren W. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;107:289–292Google Scholar
- 33.van der Meer J, Hillege HL, Ascoop CAP, Dunselman PHJ, Mulder BJM, van Ommen GVA, Pfisterer M, von Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996;75:1–3PubMedCrossRefGoogle Scholar